The mechanisms controlling BRD4 CRC targeting to the intrinsic IIR genes are not understood; using nonselective BET inhibitors, it has been observed that BRD4 binds super enhancers and cell type specification genes through its acetyl-histone binding domain (68). This evidence concerns the gene DNER and colorectal carcinoma.